Qingchuan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Qingchuan Chen has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Chengxuan Yang
Department of Galactophore, Xinxiang First People's Hospital, Xinxiang
1 shared publication- Jiaojuan Huang
School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology
1 shared publication - Jing Qu
School of basic medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication - Rongqun Guo
Translational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Department of Emergency Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Public Research Platform Management Center, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China
1 shared publication - Shuiling Jin
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
1 shared publication - Wei Wu
Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, China
1 shared publication
Latest Publications
- Open Access
- 31 January 2024
- Published by Cold Spring Harbor Laboratory in RNA
- Vol. 30 (4) , 435-447
Histone lysine demethylase KDM5B facilitates proliferation and suppresses apoptosis in human acute myeloid leukemia cells through the miR-140-3p/BCL2 axis
The histone lysine demethylase KDM5B is frequently up-regulated in various human cancer cells. However, its expression and functional role in human acute myeloid leukemia (AML) cells remain unclear. Here, we found that the expression level of KDM5B is high in primary human AML cells. We have demonstrated that knocking down KDM5B leads to apoptosis and impairs proliferation in primary human AML and some human AML cell lines. We further identified miR-140-3p as a downstream target gene of KDM5B. KDM5B expression was inversely correlated with the miR-140-3p level in primary human AML cells. Molecular studies showed that silencing KDM5B enhanced H3K4 trimethylation (H3K4me3) at the promoter of miR-140-3p, leading to high expression of miR-140-3p, which in turn inhibited B-cell CLL/lymphoma 2 (BCL2) expression. Finally, we demonstrate that the defective proliferation induced by KDM5B knockdown (KD) can be rescued with the miR-140-3p inhibitor or enhanced by combining KDM5B KD with a BCL2 inhibitor. Altogether, our data support the conclusion that KDM5B promotes tumorigenesis in human AML cells through the miR-140-3p/BCL2 axis. Targeting the KDM5B/miR-140-3p/BCL2 pathway may hold therapeutic promise for treating human AML.
- 31 January 2024
- Published by Cold Spring Harbor Laboratory in RNA
- Vol. 30 (4) , 435-447
Open AccessHistone lysine demethylase KDM5B facilitates proliferation and suppresses apoptosis in human acute myeloid leukemia cells through the miR-140-3p/BCL2 axis
The histone lysine demethylase KDM5B is frequently up-regulated in various human cancer cells. However, its expression and functional role in human acute myeloid leukemia (AML) cells remain unclear. Here, we found that the expression level of KDM5B is high in primary human AML cells. We have demonstrated that knocking down KDM5B leads to apoptosis and impairs proliferation in primary human AML and some human AML cell lines. We further identified miR-140-3p as a downstream target gene of KDM5B. KDM5B expression was inversely correlated with the miR-140-3p level in primary human AML cells. Molecular studies showed that silencing KDM5B enhanced H3K4 trimethylation (H3K4me3) at the promoter of miR-140-3p, leading to high expression of miR-140-3p, which in turn inhibited B-cell CLL/lymphoma 2 (BCL2) expression. Finally, we demonstrate that the defective proliferation induced by KDM5B knockdown (KD) can be rescued with the miR-140-3p inhibitor or enhanced by combining KDM5B KD with a BCL2 inhibitor. Altogether, our data support the conclusion that KDM5B promotes tumorigenesis in human AML cells through the miR-140-3p/BCL2 axis. Targeting the KDM5B/miR-140-3p/BCL2 pathway may hold therapeutic promise for treating human AML.